Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search

 


Widely used medicicines increase risk of rare kidney disease

Widely used heartburn and peptic ulcer medicines increase risk of rare kidney disease: Otago research


New Zealanders taking a proton pump inhibitor (PPI), a type of medicine used to treat gastric acid reflux disorders and peptic ulcer disease, are at an increased risk of a rare kidney disease, according to new findings by University of Otago researchers.

In a newly published study in the journal Kidney International, the researchers found that people who were currently taking a PPI (omeprazole, pantoprazole, or lansoprazole) were about five times more likely to be admitted to hospital with interstitial nephritis than similar people who were past users of a PPI.

Study co-author Dr Lianne Parkin says that interstitial nephritis is a rare, but potentially serious condition, involving inflammation of the kidney tissue.

“While PPIs have been shown to be an effective treatment for gastro-oesophageal reflux and peptic ulcer diseases, there is also evidence, from New Zealand and overseas, which suggests these drugs are sometimes inappropriately prescribed.

“Previous studies have suggested that PPIs increase the risk of interstitial nephritis, however our study is the largest to date and the first to confirm the relationship. We were also able to calculate the absolute risk associated with these drugs, which provides useful information for patients and doctors,” says Dr Parkin. “For example, for every 100,000 people taking a PPI, we found that about 12 per year developed interstitial nephritis as compared with 2 per 100,000 among past users.”

“The excess risk of interstitial nephritis we observed in current users of PPIs, although low in absolute terms, is important from a population perspective as PPIs are one of the most widely prescribed groups of drugs – for instance, about 20% of the New Zealand population was dispensed a PPI at least once between 2005 and 2009. In addition, New Zealanders have been able to purchase a PPI over the counter, without medical advice, since late 2009,” says Dr Parkin.

The researchers used routinely collected health and prescription medicine data to conduct a study based on 572,661 people of all ages who were dispensed omeprazole, pantoprazole, or lansoprazole at any time between 2005 and 2009. Patients with pre-existing kidney disease were excluded from the study, and other potential influences, including age, sex, and other medical conditions and prescription drugs, were taken into account in the analyses.

“Although the PPIs included in our study are extremely safe for the vast majority of users,” says Dr Parkin, “it is important for prescribers to be aware of this increased risk of interstitial nephritis, and for patients to seek appropriate advice before using these medicines.”

The research was funded by Medsafe and the Health Research Council of New Zealand.

Ends

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Media: Julian Wilcox Leaves Māori TV

Māori Television has confirmed the resignation of Head of News and Production Julian Wilcox. Mr Maxwell acknowledged Mr Wilcox’s significant contribution to Māori Television since joining the organisation in 2004. More>>

ALSO:

Genetics: New Heat Tolerant Cow Developed

Hamilton, New Zealand-based Dairy Solutionz Ltd has led an expert genetics team to develop a new dairy cow breed conditioned to thrive in lower elevation tropical climates and achieve high milk production under heat stress. More>>

Fractals: Thousands More Business Cards Needed To Build Giant Sponge

New Zealand is taking part in a global event this weekend to build a Menger Sponge using 15 million business cards but local organisers say they are thousands of business cards short. More>>

Scoop Business: NZ Net Migration Rises To Annual Record In September

New Zealand’s annual net migration rose to a record in September, beating government forecasts, as the inflow was spurred by student arrivals from India and Kiwis returning home from Australia. More>>

ALSO:

Scoop Business: Fletcher To Close Its Christchurch Insulation Plant, Cut 29 Jobs

Fletcher Building, New Zealand’s largest listed company, will close its Christchurch insulation factory, as it consolidates its Tasman Insulations operations in a “highly competitive market”. More>>

ALSO:

Scoop Business: Novartis Adds Nine New Treatments Under Pharmac Deal

Novartis New Zealand, the local unit of the global pharmaceuticals firm, has added nine new treatments in a far-ranging agreement with government drug buying agency, Pharmac. More>>

ALSO:

Crown Accounts: English Wary On Tax Take, Could Threaten Surplus

Finance Minister Bill English is warning the tax take may come in below forecast in the current financial year, as figures released today confirm it was short by nearly $1 billion in the year to June 30 and English warned of the potential impact of slumping receipts from agricultural exports. More>>

ALSO:

Get More From Scoop

 
 
Standards New Zealand

Standards New Zealand

Mosh Social Media
 
 
 
 
 
 
 
 
Sci-Tech
Search Scoop  
 
 
Powered by Vodafone
NZ independent news